Buy Local, Buy Wisconsin Grants 2025

The FY24 BCRP Clinical Research Extension Award is designed to enhance the impact of previously funded breast cancer clinical studies by extending or expanding data collection, follow-up, and analysis. This mechanism directly aligns with the broader mission of maximizing the value of breast cancer patient participation in clinical research, thereby addressing knowledge gaps that may arise from early trial termination, limited patient follow-up, or insufficient data collection and analysis. By ensuring that the invaluable contributions of patient tissues, serum, other biological specimens, and data are fully utilized, the BCRP aims to ensure that scientific efforts truly value these contributions and maximize their impact in saving lives. The primary target beneficiaries of this award are breast cancer patients and the scientific community. The impact goals are to increase the clinically relevant impact of breast cancer patient participation, accelerate progress toward ending breast cancer, and generate meaningful hypotheses or support valid conclusions. The program prioritizes research that extends or affects the impact of previous clinical trials or studies, or creates new impact in the fight against breast cancer. It specifically encourages innovative research in nuclear medicine to support early diagnosis, more effective treatment, and improved health outcomes for active-duty Service Members, Veterans, military beneficiaries, and the American public. Key focuses for the research scope include deeper molecular analysis of clinical samples, initiation of new correlative studies, biomarker validation, or continued clinical follow-up of patients in open, ongoing, or completed clinical trials. The proposed research can be hypothesis-testing or -generating, and may also be designed to create clinically annotated and molecularly characterized experimental platforms, such as patient-derived models or tissue arrays. Innovation is not a primary criterion for this award, and projects proposing new clinical trials will not be supported. A critical focus is on meaningful and productive partnerships between investigators, with a Partnering PI Option available to accommodate two Principal Investigators who bring distinct and equally intellectual contributions to the project. Expected outcomes include increased understanding of breast cancer through extended data analysis, validation of biomarkers, improved patient follow-up, and the development of new experimental platforms. Measurable results are tied to valid conclusions from appropriately sized study samples and a clear data-sharing plan to ensure the scientific community has access to generated platforms and molecular data. The program also emphasizes robust research teams with relevant expertise and mandatory involvement of two or more breast cancer consumer advocates who provide objective input on the research's potential impact for individuals with, or at risk for, breast cancer. The overall strategic priority is to accelerate clinical and translational research, especially for advanced state and recurrent patients, and to improve health outcomes for military service members and the public through relevant collaborations and innovative techniques.